Compare PAI & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PAI | ACOG |
|---|---|---|
| Founded | 1973 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 130.9M |
| IPO Year | N/A | N/A |
| Metric | PAI | ACOG |
|---|---|---|
| Price | $12.36 | $5.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 25.0K | ★ 81.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $143.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.59 | $3.75 |
| 52 Week High | $12.63 | $11.54 |
| Indicator | PAI | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 41.14 |
| Support Level | $12.36 | $5.66 |
| Resistance Level | $12.44 | $6.74 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.05 | 2.75 |
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.